IHF:NYE-iShares U.S. Healthcare Providers ETF (USD)

ETF | Health |

Last Closing

USD 57.63

Change

+0.17 (+0.30)%

Market Cap

N/A

Volume

0.07M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.26 (-0.17%)

USD 42.19B
FHLC Fidelity® MSCI Health Care In..

-0.02 (-0.03%)

USD 3.02B
FXH First Trust Health Care AlphaD..

-0.02 (-0.02%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

-0.11 (-0.12%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.09 (-0.38%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

+0.40 (+1.07%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

+0.43 (+0.44%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.05 (-0.17%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.19 (-0.29%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.22 (+0.76%)

USD 0.01B

ETFs Containing IHF

LCR Leuthold Core ETF 4.25 % 0.00 %

-0.01 (-0.02%)

USD 0.09B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.75% 43% F 60% D-
Dividend Return 0.25% 40% F 4% F
Total Return 10.00% 43% F 52% F
Trailing 12 Months  
Capital Gain 15.76% 29% F 58% F
Dividend Return 0.85% 61% D- 10% F
Total Return 16.61% 33% F 51% F
Trailing 5 Years  
Capital Gain 69.10% 100% F 79% B-
Dividend Return 4.27% 61% D- 12% F
Total Return 73.37% 90% A- 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 9.25% 90% A- 67% D+
Dividend Return 9.88% 81% B- 62% D
Total Return 0.63% 63% D 14% F
Risk Return Profile  
Volatility (Standard Deviation) 16.94% 57% F 59% D-
Risk Adjusted Return 58.29% 71% C- 76% C+
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

What to not like:

There is nothing we particularly dislike